4.5 Article

The Economic Impact of Non-Melanoma Skin Cancer: A Review

期刊

出版社

HARBORSIDE PRESS
DOI: 10.6004/jnccn.2010.0066

关键词

Non-melanoma skin cancer; treatments; care settings; Medicare; costs; basal cell carcinoma; squamous cell carcinoma; BCC; SCC

类别

资金

  1. Galderma
  2. GlaxoSmithKline/Stiefel Laboratories Inc.
  3. Astellas
  4. Abbott Laboratories
  5. Warner Chilcott
  6. Centocor, Inc.
  7. Amgen Inc.
  8. Photomedex
  9. Coria/Healthpoint/Valeant
  10. Pharmaderm/Nycomed
  11. Dermatology Foundation
  12. American Society for Dermatologic Surgery
  13. American Acne Rosacea Society
  14. National Psoriasis Foundation
  15. Ortho Pharmaceuticals
  16. Aventis Pharmaceuticals
  17. Roche Dermatology
  18. 3M
  19. Bristol-Myers Squibb Dermatology
  20. Novartis Pharmaceuticals Corporation
  21. Merck Co., Inc.
  22. Xlibris
  23. Suncare Research
  24. Pep lin
  25. Medscape
  26. Kikaku
  27. Caremark
  28. Informa
  29. Medical Quality Enhancement Corporation

向作者/读者索取更多资源

Non-melanoma skin cancer (NMSC) is the most common cancer in the United States. Cost of NMSC care primarily depends on 2 factors: care settings and treatment modalities. However, the cost efficacy of NMSC care has been insufficiently addressed in previous literature. Therefore, this article evaluates available research on the cost implications to compare the costs associated with treatment within different care settings and specialties involved, and to assess the costs of different treatment modalities with respect to procedure type, tumor size, and tumor location. This evaluation showed that physician-office settings provided the lowest cost per episode of care ($492) and were the dominant setting for NMSC care; dermatologists managed most NMSC episodes and used a wider range of treatment options than other specialists. Regarding treatment modalities, Mohs micrographic surgery was shown to be similar in cost to traditional surgical excision with permanent sections and was less costly than excision with frozen sections. Electrodessication and curettage and imiquimod were also reported to be inexpensive treatments. Furthermore, a positive correlation was seen between cost and tumor size for any particular treatment modality. Given these comparisons, and the rising incidence of NMSC and potential legislative measures to regulate office-based procedures, it is important to preserve the low-cost management of this disease. (JNCCN 2010;8:888-896)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据